Novo Nordisk is planning a higher-dose version (CagriSema 2.4/7.2 mg, pairing standard cagrilintide with Wegovy HD-level semaglutide) in a new Phase 3 trial starting H2 2026
Thats why were blunt about who actually qualifies for a peptide, instead of handing one to every 32-year-old chasing a protocol they saw online
5mg and 10mg lyophilized vials
However, emerging research also links gut barrier dysfunction to systemic conditions including autoimmune diseases, body syndrome, obesity, type 2 diabetes, non-alcoholic fatty liver disease, heart disease, and even neurological and psychiatric conditions through the gut-brain axis
Nature 436 , 415419 (2005)